SCHEMBL3336175

SCHEMBL3336175

O=C(Nc1cccc(Cl)c1)Nc1ccccc1C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 1.00
NPC1 O15118 4/20 1.00
RAB9A P51151 4/20 1.00
GRIK1 P39086 8/20 0.79
DHODH Q02127 1/20 0.78
MEN1 O00255 5/20 0.77
KMT2A Q03164 5/20 0.77
MAPT P10636 5/20 0.71
ALDH1A1 P00352 4/20 0.71
LMNA P02545 2/20 0.71
HTT P42858 2/20 0.71
L3MBTL1 Q9Y468 1/20 0.71
NFKB1 P19838 1/20 0.70
GFER P55789 1/20 0.70
NFKB2 Q00653 1/20 0.70
RELA Q04206 1/20 0.70
SMN1; SMN2 Q16637 1/20 0.70
GRIK2 Q13002 1/20 0.64
PPIA P62937 1/20 0.63
GAA P10253 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6823566 0.92 RAB9A (0.85) KDM4ENPC1RAB9AGRIK1DHODH
SCHEMBL3961840 0.88 GRIK1 (1.00) KDM4ENPC1RAB9AGRIK1MEN1
SCHEMBL11983339 0.88 DHODH (1.00) KDM4ENPC1RAB9AGRIK1DHODH
SCHEMBL4301183 0.88 KMT2A (0.82) KDM4ENPC1RAB9AGRIK1MEN1
SCHEMBL23831528 0.87 KDM4E (1.00) KDM4ENPC1RAB9AGRIK1DHODH
SCHEMBL16495781 0.86 MEN1 (0.76) KDM4ENPC1RAB9AGRIK1DHODH
SCHEMBL30235534 0.85 KMT2A (0.76) KDM4ENPC1RAB9AGRIK1DHODH
SCHEMBL23831294 0.85 KDM4E (0.73) KDM4ENPC1RAB9AGRIK1DHODH
SCHEMBL23831265 0.85 KMT2A (0.76) KDM4ENPC1RAB9AGRIK1DHODH
SCHEMBL10344695 0.84 MEN1 (1.00) KDM4ENPC1RAB9AGRIK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144872-A1 New Methylenebisphenyl Compounds Useful in the Treatment of Inflammation BIOLIPOX AB 2010-06-10 US disclosed
EP-0809492-A4 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2007-01-24 EP disclosed
US-6900219-B2 ABCA-1 elevating compounds CV THERAPEUTICS, INC. (US) 2005-05-31 US disclosed
CN-1539816-A IL-8 receptor antagonists ʷ��˿�������ȳ�ķ���޹�˾ 2004-10-27 CN disclosed
EP-1185261-A4 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2004-02-25 EP disclosed
US-20030220356-A1 ABCA-1 elevating compounds CV THERAPEUTICS, INC. 2003-11-27 US disclosed
US-20020128321-A1 IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION 2002-09-12 US disclosed
CN-1355697-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORP (US) 2002-06-26 CN disclosed
EP-1185261-A1 IL-8 RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2002-03-13 EP disclosed
US-6262113-B1 HYDROXY- OR MERCAPTO-PHENYLUREAS SMITHKLINE BEECHAM CORPORATION 2001-07-17 US disclosed
US-6211373-B1 Phenyl urea antagonists of the IL-8 receptor SMITHKLINE BEECHAM CORPORATION 2001-04-03 US disclosed
US-6180675-B1 THERAPY FOR CHEMOKINE SENSITIVE DISEASE; USING A AROMATIC (THIO)UREA COMPOUND SMITHKLINE BEECHAM CORPORATION 2001-01-30 US disclosed
WO-2000076495-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2000-12-21 WO disclosed
US-6005008-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 1999-12-21 US disclosed
CN-1215990-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORP (US) 1999-05-05 CN disclosed
US-5886044-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 1999-03-23 US disclosed
US-5780483-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 1998-07-14 US disclosed
EP-0809492-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-12-03 EP disclosed
WO-1996025157-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1996-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220356-A1 ABCA-1 elevating compounds ABCD3, ABCE1, ABCB4 KDM4E 4506/4885NPC1 6/4885RAB9A 2138/4885
US-20020128321-A1 IL-8 receptor antagonists CXCL8, CCR8, IL1RN KDM4E 3818/4885NPC1 1517/4885RAB9A 1746/4885
US-20100144872-A1 New Methylenebisphenyl Compounds Useful in the Treatment of Inflammation LTC4S, LTB4R2, LTB4R KDM4E 2928/4885NPC1 2854/4885RAB9A 3715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.